Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467695 | 0.94 | CHRM4 (0.32) | GLSCHRM4MAOBNOX1KMT2A | |
| SCHEMBL6029059 | 0.92 | FFAR1 (0.34) | GLSCHRM4 | |
| SCHEMBL6026677 | 0.89 | CSNK2A2 (0.32) | — | |
| SCHEMBL6026821 | 0.88 | MAPT (0.32) | GAAKDM4EKMT2AMEN1 | |
| SCHEMBL5791121 | 0.84 | STING1 (0.36) | GLSGAANR1H4KDM4EPOLB | |
| SCHEMBL6027097 | 0.84 | MRGPRX4 (0.36) | GAAKDM4EPOLBMAOBKMT2A | |
| SCHEMBL4762897 | 0.82 | PIK3CD (0.39) | GLSGAANR1H4KDM4EPOLB | |
| SCHEMBL6029049 | 0.82 | MEN1 (0.33) | POLBKMT2AMEN1 | |
| SCHEMBL5794401 | 0.82 | PIK3CD (0.36) | GLSGAANR1H4KDM4EPOLB | |
| SCHEMBL5794381 | 0.78 | GLS (0.33) | GLSGAAKDM4EL3MBTL1NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664037-A1 | HALO SUBSTITUTED BENZO [B] THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | CONNOLLY MICHAEL K (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005023800-A1 | HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | HCLS1, BRI3BP, BRPF1 | GLS 828/4885GAA 2724/4885CHRM4 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.